Valuation dashboard for Stryker Corporation (SYK) with P/E 27.82, P/B 4.33, EV/EBITDA 19.02 and dividend yield 1.29%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries.
Analysis Summary
Stryker Corporation reported revenue of $25.12B in the most recent fiscal year, growing at a 5-year CAGR of 11.8%. Net income reached $3.25B, with a 15.2% 5-year CAGR.
Trailing-twelve-month margins: gross margin 65.2%, operating margin 22.0%, net margin 14.4%.
At the current price of $275.12, SYK trades at a P/E of 27.82 and an ROE of 16.36%. Market capitalisation stands at $105.5B, placing it among large-cap names.
Balance sheet quality for SYK: current ratio of 1.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 27.82 |
| Price / Book | 4.33 |
| EV / EBITDA | 19.02 |
| Dividend Yield | 1.29% |
Valuation Models
| DCF Fair Value | $286.57 |
| vs Current Price | +4.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SYK | Stryker Corporation | $105.5B | 27.82 | 4.33 | 16.4% |
| BSX | Boston Scientific Corporation | $64.4B | 17.49 | 2.57 | 14.9% |
| AMGN | Amgen Inc. | $208.1B | 23.77 | 17.81 | 89.3% |
| GILD | Gilead Sciences, Inc. | $186.4B | 15.68 | -16.3% | |
| PFE | Pfizer Inc. | $157.3B | 36.38 | 1.84 | 9.0% |
| DHR | Danaher Corporation | $148.9B | 39.21 | 2.97 | 7.7% |
| MDT | Medtronic plc | $117.9B | 22.29 | 2.32 | 10.6% |
| HCA | HCA Healthcare, Inc. | $92.6B | 14.39 | -112.6% |
Price
| Price | $275.12 |
| Market Cap | $105.5B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 16.36% |
| Return on Invested Capital | 9.82% |
| Return on Assets | 7.78% |
| Gross Margin | 65.17% |
| Operating Margin | 22.03% |
| Net Margin | 14.43% |
Related companies: AMGN · BSX · DHR · GILD · HCA · MCK · MDT
Explore sector: Healthcare · Medical - Devices
More sections of SYK: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks